Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register
Abstract Objectives To assess whether age, at the beginning of biologic treatment, is associated with the time a first adverse event (AE) appears in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis (PsA). Methods All patients in the BIOBADASER registry dia...
Main Authors: | Paloma Vela, Carlos Sanchez-Piedra, Carolina Perez-Garcia, María C. Castro-Villegas, Mercedes Freire, Lourdes Mateo, Cesar Díaz-Torné, Cristina Bohorquez, Juan M. Blanco-Madrigal, Inmaculada Ros-Vilamajo, Silvia Gómez, Rocio Caño, Fernando Sánchez-Alonso, Federico Díaz-González, Juan J. Gómez-Reino |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-06-01
|
Series: | Arthritis Research & Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13075-020-02231-x |
Similar Items
-
Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line
by: Svedbom A, et al.
Published: (2017-01-01) -
Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion
by: Jozélio Freire de Carvalho, et al.
Published: (2018-08-01) -
Body Mass Index and Disease Activity in Chronic Inflammatory Rheumatic Diseases: Results of the Cardiovascular in Rheumatology (Carma) Project
by: Jesús A. Valero-Jaimes, et al.
Published: (2021-01-01) -
Systemic Inflammatory Response and Atherosclerosis: The Paradigm of Chronic Inflammatory Rheumatic Diseases
by: Aikaterini Arida, et al.
Published: (2018-06-01) -
Bone phenotypes in rheumatology – there is more to bone than just bone
by: Christian S. Thudium, et al.
Published: (2020-11-01)